Former EMA boss Lönngren proposes hard Brexit solution
Executive Summary
Pharma is clearly worried about how the UK's exit from the EU will disrupt both the European Medicines Agency's capacity for drugs reviews and the pan-European regulatory environment. Former EMA executive director Thomas Lönngren explained to the Pink Sheet during the BIO-Europe Spring meeting that the relationship between EMA and the US Food and Drug Administration could be a model the UK regulator, the MHRA, could adopt if the British take a hard Brexit route.